Search

Your search keyword '"Peserico, Andrea"' showing total 288 results
Start Over Author "Peserico, Andrea"
288 results on '"Peserico, Andrea"'

1. Ciclosporin-responsive pyoderma in dogs: A comparison to human pyoderma gangrenosum.

Author

De Lucia, Michela, Orlandini, Paola, Denti, Daria, Berto, Laura, Mezzalira, Giorgia, Peserico, Andrea, and Fortina, Anna Belloni

Subjects
PYODERMA gangrenosum, C-reactive protein, BACTERIAL diseases, CYCLOSPORINE, DOGS
Abstract

We describe 20 cases of canine pyoderma responsive to immunosuppressive treatments and resembling human pyoderma gangrenosum. All dogs presented with a rapidly evolving, focal to multifocal, painful ulcerative dermatitis, non-responsive to multiple antibiotic and anti-inflammatory therapies. Elevations of C-reactive protein (100%), neutrophilia (75%) and fever (25%) were also present. Histopathology showed a severe, ulcerative, superficial to deep, predominantly neutrophilic dermatitis. Bacterial infection was the most challenging differential diagnosis. Resolution of the lesions was obtained within 4-8 weeks in 83% of dogs treated with ciclosporin. Maintenance treatment was required in the majority of the dogs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Squamous Cell Carcinoma

Author

Fortina, Anna Belloni, Piaserico, Stefano, Alaibac, Mauro, Peserico, Andrea, Rosen, Steven T., editor, Stockfleth, Eggert, editor, and Ulrich, Claas, editor

Published
2009
Full Text
View/download PDF

4. Italian Euromelanoma Day Screening Campaign (2005–2007) and the planning of melanoma screening strategies

Author

Seidenari, Stefania, Benati, Elisa, Ponti, Giovanni, Borsari, Stefania, Ferrari, Chiara, Albertini, Giuseppe, Altomare, Gianfranco, Arcangeli, Fabio, Aste, Nicola, Bernengo, Maria Grazia, Bongiorno, Maria Rita, Borroni, Giovanni, Calvieri, Stefano, Chimenti, Sergio, Cusano, Francesco, Fracchiolla, Claudio, Gaddoni, Giuseppe, Girolomoni, Giampiero, Guarneri, Biagio, Lanzoni, Anna, Lombardi, Mara, Lotti, Torello, Mariotti, Antonio, Marsili, Franco, Micali, Giuseppe, Parodi, Aurora, Peris, Ketty, Peserico, Andrea, Quaglino, Pietro, Santini, Marcello, Schiavon, Sergio, Tonino, Camillo, Trevisan, Giusto, Tribuzi, Paola, Valentini, Paolo, Vena, Gino A., and Virgili, Annarosa

Published
2012

6. 26874 Long-term efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who were partial responders or nonresponders to etanercept: Post hoc analysis through 5 years from the reSURFACE 2 phase 3 trial

Author

Thaçi, Diamant, primary, Griffiths, Christopher E.M., additional, Iversen, Lars, additional, Peserico, Andrea, additional, Pau-Charles, Ignasi, additional, Blauvelt, Andrew, additional, and Reich, Kristian, additional

Published
2021
Full Text
View/download PDF

7. Patch test results in children and adolescents across Europe. Analysis of the ESSCA Network† 2002–2010

Author

Belloni Fortina, Anna, Cooper, Susan M., Spiewak, Radoslaw, Fontana, Elena, Schnuch, Axel, Uter, Wolfgang, Aberer, Werner, Bircher, Andreas, Simon, Dagmar, Ballmer-Weber, Barbara, Frosch, Peter, Fuchs, Thomas, Brasch, Jochen, Bauer, Andrea, Elsner, Peter, John, Swen Malte, Mahler, Vera, Weisshaar, Elke, Johansen, Jeanne Duus, Giménez Arnau, Ana, Sánchez-Pérez, Javier, Fco. Silvestre, Juan, García-Gavín, Juan, Fernández-Redondo, Virginia, Carlos Amario-Hita, José, Rantanen, Tapio, Ayala, Fabio, Balato, Anna, Peserico, Andrea, Filon, Francesca Larese, Wallnofer, W., Corradin, Maria Teresa, Gallo, Rosella, Coenraads, Pieter-Jan, Schuttelaar, Marie-Louise, Rustemeyer, Thomas, Krecicz, Beata, Kieć-Świerczyńska, Marta, Czarnecka-Operacz, Magdalena, Sadowska, Anna, Dugonik, Aleksandra, Pandurovic, Maja Kalac, Kmecl, Tanja, Vok, Marko, Orton, David I., Green, Cathy M., Wilkinson, Mark, Sansom, Jane E., King, Codagh M., Horne, Helen L., English, John S.C., Graham, Johnston, Statham, Barry N., Chowdhury, Mahbub M.U., Stone, Natalie, Cooper, Sue, Gawkrodger, David J., and Ormerod, Anthony D.

Published
2015
Full Text
View/download PDF

8. Reply to Scalone and Cortesi: “Cost-Utility Analysis of Biologic Therapies to Treat Chronic Plaque Psoriasis in Italy: The Importance of Using Updated and Adequate Social Tariffs to Calculate QALYs”

Author

Spandonaro, Federico, Ayala, Fabio, Berardesca, Enzo, Chimenti, Sergio, Girolomoni, Giampiero, Martini, Patrizia, Peserico, Andrea, Polistena, Barbara, Guerra, Antonio Puglisi, Vena, Gino Antonio, Altomare, Gianfranco, and Pinton, Piergiacomo Calzavara

Published
2015
Full Text
View/download PDF

11. Allergic contact sensitivity in elderly patients

Author

Piaserico, Stefano, Larese, Francesca, Recchia, Giovanni Piero, Corradin, Maria Teresa, Scardigli, Franco, Gennaro, Francesco, Carriere, Cinzia, Semenzato, Alessandra, Brandolisio, Lara, Peserico, Andrea, Fortina, Anna Belloni, and the NEICDG

Published
2004
Full Text
View/download PDF

13. Squamous Cell Carcinoma

Author

Fortina, Anna Belloni, primary, Piaserico, Stefano, additional, Alaibac, Mauro, additional, and Peserico, Andrea, additional

Published
2009
Full Text
View/download PDF

14. Current patch test results with the European baseline series and extensions to it from the ‘European Surveillance System on Contact Allergy’ network, 2007–2008

Author

Uter, Wolfgang, Aberer, Werner, Armario-Hita, José Carlos, Fernandez-Vozmediano, José M., Ayala, Fabio, Balato, Anna, Bauer, Andrea, Ballmer-Weber, Barbara, Beliauskiene, Aiste, Fortina, Anna Belloni, Bircher, Andreas, Brasch, Jochen, Chowdhury, Mahbub M. U., Coenraads, Pieter-Jan, Schuttelaar, Marie-Louise, Cooper, Sue, Czarnecka-Operacz, Magda, Zmudzinska, Maria, Elsner, Peter, English, John S. C., Frosch, Peter J., Fuchs, Thomas, García-Gavín, Juan, Fernández-Redondo, Virginia, Gawkrodger, David J., Giménez-Arnau, Ana, Green, Cathy M., Horne, Helen L., Johansen, Jeanne Duus, Jolanki, Riitta, Pesonen, Maria, King, Clodagh M., Krêcisz, Beata, Chomiczewska, Dorota, Kiec-Swierczynska, Marta, Larese, Francesca, Mahler, Vera, Ormerod, Anthony D., Peserico, Andrea, Rantanen, Tapio, Rustemeyer, Thomas, Sánchez-Pérez, Javier, Sansom, Jane E., Silvestre, Juan Fco., Simon, Dagmar, Spiewak, Radoslaw, Statham, Barry N., Stone, Natalie, Wilkinson, Mark, and Schnuch, Axel

Published
2012
Full Text
View/download PDF

20. The European baseline series in 10 European Countries, 2005/2006 – Results of the European Surveillance System on Contact Allergies (ESSCA)

Author

Uter, Wolfgang, Rämsch, Christiane, Aberer, Werner, Ayala, Fabio, Balato, Anna, Beliauskiene, Aiste, Fortina, Anna Belloni, Bircher, Andreas, Brasch, Jochen, Chowdhury, Mahbub M. U., Coenraads, Pieter-Jan, Schuttelaar, Marie-Louise, Cooper, Sue, Corradin, Maria Teresa, Elsner, Peter, English, John S. C., Fartasch, Manigè, Mahler, Vera, Frosch, Peter J., Fuchs, Thomas, Gawkrodger, David J., Gimènez-Arnau, Ana-Maria, Green, Cathy M., Horne, Helen L., Jolanki, Riitta, King, Codagh M., Krêcisz, Beata, Kiec-Swierczynska, Marta, Ormerod, Anthony D., Orton, David I., Peserico, Andrea, Rantanen, Tapio, Rustemeyer, Thomas, Sansom, Jane E., Simon, Dagmar, Statham, Barry N., Wilkinson, Mark, and Schnuch, Axel

Published
2009
Full Text
View/download PDF

25. Cigarette Smoking, Body Mass Index, and Stressful Life Events as Risk Factors for Psoriasis: Results from an Italian Case–Control Study

Author

Naldi, Luigi, Chatenoud, Liliane, Linder, Dennis, Fortina, Anna Belloni, Peserico, Andrea, Virgili, Anna Rosa, Bruni, Pier Luigi, Ingordo, Vito, Scocco, Giovanni Lo, Solaroli, Carmen, Schena, Donatella, Barba, Annalisa, Di Landro, Anna, Pezzarossa, Enrico, Arcangeli, Fabio, Gianni, Claudia, Betti, Roberto, Carli, Paolo, Farris, Alessandro, Barabino, Gian Franco, and Vecchia, Carlo La

Published
2005

40. Life Events and Alopecia areata

Author

Perini, Giulia I., Fornasa, Cleto Veller, Cipriani, Roberto, Bettin, Annalisa, Zecchino, Francesco, and Peserico, Andrea

Published
1984

41. Physician–patient communication and patient‐reported outcomes in the actinic keratosis treatment adherence initiative (AK‐TRAIN): a multicenter, prospective, real‐life study of treatment satisfaction, quality of life and adherence to topical field‐directed therapy for the treatment of actinic keratosis in Italy

Author

Ayala, Fabio, Quaglino, Pietro, Cannavò, Serafinella, Rubegni, Pietro, Ferreli, Caterina, Girolomoni, Gianpiero, Bongiorno, Maria Rita, Potenza, Concetta, Micali, Giuseppe, Pimpinelli, Nicola, Romanelli, Marco, Stanganelli, Ignazio, Bonamonte, Domenico, Peserico, Andrea, Fargnoli, Maria Concetta, Pinton, Piergiacomo Calzavara, Costanzo, Domenico, Cantisani, Carmen, Borsari, Stefania, and Ricci, Francesco

Abstract

Background: Patients with multiple actinic keratoses (AKs) should be treated with field‐directed therapy. Such treatments challenge patients' adherence due to out‐of‐pocket costs, length of treatment and severity of local skin reactions (LSRs). Effective physician–patient communication (PPC) may buffer therapy‐related distress, thus improving quality of life, treatment satisfaction and adherence. Objectives: We evaluated the interplay between PPC, LSR intensity (safety) and lesion clearance rates (effectiveness) on treatment satisfaction, quality of life and treatment adherence among patients with multiple AKs receiving topical field‐directed therapies. Methods: In this observational, multicentre, longitudinal, cohort study, we included 1136 adult patients with discrete, clinically detectable, visible, multiple (three or more lesions in a 25 cm2 area), Grade I/II AKs, for whom the attending dermatologist has prescribed treatment with a topical field‐directed therapy. We matched self‐reported data and medical information recorded by dermatologists in standard clinical forms. Patients were followed up at two time points (T1: 8 days; T2: 25–30 days) Results: Most patients were elderly, married, men with poor socio‐economic status and multiple lesions of the scalp or face. The majority (n = 961) had a prescription of ingenol mebutate (IMB) and 175 received either diclofenac 3% in hyaluronic acid (DHA) or imiquimod 5% (IMQ). Clearance rate at 1 month was 84%. Most patients felt very supported (n = 819, 73%) and rated dermatologist's explanations very clear (n = 608, 54%). Treatment satisfaction (effectiveness and convenience scales) increased along the follow‐up, especially for those on IMB (Δpre‐post = −4.00; other: Δpre‐post = −0.25; interaction P < 0.001). Communication clarity was associated with higher treatment satisfaction scores (β = 0.4–0.6, P < 0.01) and lower risk of non‐adherence among IMB patients (risk difference: 16%, P < 0.01). Conclusion: Communication clarity was associated with patient‐reported outcomes and adherence beyond AK‐related clinical parameters. Our study questions the current episodic approach to AK management and provides the rationale to develop chronic care models fostering patients' engagement and treatment alliance. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

42. Psoriasis:The Life Course Approach

Author

Linder, Michael Dennis, Piaserico, Stefano, Augustin, Matthias, Fortina, Anna Belloni, Cohen, Arnon D, Gieler, Uwe, Jemec, Gregor B E, Kimball, Alexa Boer, Peserico, Andrea, Sampogna, Francesca, Warren, Richard B, de Korte, John, Linder, Michael Dennis, Piaserico, Stefano, Augustin, Matthias, Fortina, Anna Belloni, Cohen, Arnon D, Gieler, Uwe, Jemec, Gregor B E, Kimball, Alexa Boer, Peserico, Andrea, Sampogna, Francesca, Warren, Richard B, and de Korte, John

Abstract

Over the last decades, Life Course Research (LCR), predominantly the domain of sociology, has been increasingly applied in health research, as Life Course Epidemiology (LCE). The latter is concerned with disease patterns over time, accumulation of exposures over time, critical time periods and patterns of risk. We argue that concepts from LCR and LCE could be widely applied in dermatology, in general, and, more precisely, in the study of chronic inflammatory skin diseases, e.g. atopic eczema and psoriasis. The life course approach can generally be applied in two different ways. It may be used in the more traditional manner, in which the disease and its patterns over time are examined as the outcome vari-able. Conversely, it can examine life course as the outcome variable, which is dependent on the disease course, the treatments administered, and other physical or psychosocial environmental exposures. In dermatology, this second application of the LCR concepts is both promising and relevant because of the notable impact of chronic skin diseases on the patients' quality of life. In particular, we argue how LCR may be conducive to a better understanding of the concept of 'Cumulative Life Course Impairment', which is increasingly gaining acceptance. This approach helps identifying not only individuals at risk and particularly vulnerable patients but also critical periods for optimising interventions in order to avoid life course impairment. It also may facilitate more appropriate treatment decisions in clinical practice.

Published
2016

45. Assessing the Impact of Atopic Dermatitis on the Patients' Parents with the Visual Instrument ‘Caregiver-PRISM'

Author

Marinello, Elena, primary, Linder, Dennis, additional, Spoto, Andrea, additional, Palmer, Katie, additional, Rohrer, Peter Michael, additional, Büchi, Stefan, additional, Trapp, Michael, additional, Trapp, Eva-Maria, additional, Hoerlesberger, Nina, additional, Piaserico, Stefano, additional, Peserico, Andrea, additional, Gatta, Michela, additional, and Belloni Fortina, Anna, additional

Published
2016
Full Text
View/download PDF

47. In Vitro Evaluation of Sunscreens: An Update for the Clinicians

Author

Pelizzo, Maria, Zattra, Edoardo, Nicolosi, Piergiorgio, Peserico, Andrea, Garoli, Denis, and Alaibac, Mauro

Subjects
Article Subject
Abstract

Topical sunscreens contain molecules or molecular complexes that can absorb, reflect, or scatter UV photons. Evaluation of the efficacy of sunscreen products has been made through the Sun Protection Factor (SPF), a mean of quantitatively assessing in vivo the degree of protection offered by sunscreen products against solar radiation. In vivo evaluation of SPF has several drawbacks. First of all, this evaluation method is expensive in terms of money and time. Moreover, it raises several ethical issues concerning the potential damage to skin volunteers. Several in vitro techniques have been developed, but at present there is no broadly accepted method. In this paper, we will discuss some of the recent advances concerning the in vitro evaluation of sunscreens which would be acceptable for replacing in vivo assays.

Published
2012
Full Text
View/download PDF

50. Psoriasis - The Life Course Approach.

Author

LINDER, M. Dennis, PIASERICO, Stefano, AUGUSTIN, Matthias, BELLONI FORTINA, Anna, COHEN, Arnon D., GIELER, Uwe, JEMEC, Gregor B. E., KIMBALL, Alexa B., PESERICO, Andrea, SAMPOGNA, Francesca, WARREN, Richard B., and DE KORTE, John

Subjects
PSORIASIS, EPIDEMIOLOGY, PSYCHOSOCIAL factors, QUALITY of life, SKIN inflammation
Abstract

Over the last decades, Life Course Research (LCR), predominantly the domain of sociology, has been increasingly applied in health research, as Life Course Epidemiology (LCE). The latter is concerned with disease patterns over time, accumulation of exposures over time, critical time periods and patterns of risk. We argue that concepts from LCR and LCE could be widely applied in dermatology, in general, and, more precisely, in the study of chronic inflammatory skin diseases, e.g. atopic eczema and psoriasis. The life course approach can generally be applied in two different ways. It may be used in the more traditional manner, in which the disease and its patterns over time are examined as the outcome variable. Conversely, it can examine life course as the outcome variable, which is dependent on the disease course, the treatments administered, and other physical or psychosocial environmental exposures. In dermatology, this second application of the LCR concepts is both promising and relevant because of the notable impact of chronic skin diseases on the patients' quality of life. In particular, we argue how LCR may be conducive to a better understanding of the concept of 'Cumulative Life Course Impairment', which is increasingly gaining acceptance. This approach helps identifying not only individuals at risk and particularly vulnerable patients but also critical periods for optimising interventions in order to avoid life course impairment. It also may facilitate more appropriate treatment decisions in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results